Yes, Gfp: never a dull moment with Cortex. Again, I want to stay measured with my comments regarding Stoll and Coleman. As one observer of Cortex(a money man)has told me, "The problem with Cortex is not enough management," meaning more oversight, more positions deaing with the FDA ect. If management is stretched to the limit as we speak(Stoll wearing three to four hats), how does bringing in another in-licensed product help matters? I would be against in-licensing in 99 % of cases. Of course, if Stoll and company can pull out the 1 % of gold, that's another story. My angst here is not using all availabe resources to mine the gold I believe to be in the Ampakine estate.
News 
Market Data 
Discover 
AI
